AGED Diagnostics Liver Disease Assessment

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

September 15, 2025

Conditions
NASH With FibrosisNAFLDHealthy
Interventions
DIAGNOSTIC_TEST

AGED Multiple Target Assay in Healthy Controls

Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to healthy controls

DIAGNOSTIC_TEST

AGED Multiple Target Assay in NAFLD Participants

Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to NAFLD participants (defined as simple steatosis through NASH)

DIAGNOSTIC_TEST

AGED Multiple Target Assay in Fibrosis Participants

Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to liver fibrosis stage (F0-F4)

Trial Locations (1)

20002

AGED Diagnostics, Bethesda

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Arizona Clinical Trials

UNKNOWN

collaborator

Walter Reed National Military Medical Center

FED

lead

Active Genomes Expressed Diagnostics, Corp

INDUSTRY

NCT06348563 - AGED Diagnostics Liver Disease Assessment | Biotech Hunter | Biotech Hunter